(Q46750687)

English

Phase II study of carboxyamidotriazole in patients with advanced renal cell carcinoma refractory to immunotherapy: E4896, an Eastern Cooperative Oncology Group Study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/16222691

Phase II study of carboxyamidotriazole in patients with advanced renal cell carcinoma refractory to immunotherapy: E4896, an Eastern Cooperative Oncology Group Study (English)

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/16222691

1 reference

based on heuristic

inferred from title

carboxyamidotriazole

1 reference

based on heuristic

inferred from title

renal cell carcinoma

1 reference

based on heuristic

inferred from title

Eastern Cooperative Oncology Group

7

object named as

Eastern Cooperative Oncology Group

1 reference

Europe PubMed Central

24 December 2017

6

object named as

George Wilding

1 reference

Europe PubMed Central

24 December 2017

Janice P Dutcher

1

object named as

Janice P Dutcher

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/16222691

author name string

Larry Leon

2

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/16222691

Judith Manola

3

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/16222691

David M Friedland

4

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/16222691

Bruce Roth

5

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/16222691

language of work or name

0 references

publication date

1 December 2005

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/16222691

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/16222691

104

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/16222691

2392-2399

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/16222691

11

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/16222691

Uncommon presentations of Hodgkin's disease. Case 1. Hodgkin's disease of the jejunum.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21473

21 January 2018

Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21473

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21473

7 January 2021

based on heuristic

inferred from DOI database lookup

Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21473

7 January 2021

based on heuristic

inferred from DOI database lookup

Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21473

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21473

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21473

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21473

7 January 2021

based on heuristic

inferred from DOI database lookup

Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21473

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of thalidomide for patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21473

7 January 2021

based on heuristic

inferred from DOI database lookup

Thalidomide is an inhibitor of angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21473

7 January 2021

based on heuristic

inferred from DOI database lookup

Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21473

7 January 2021

based on heuristic

inferred from DOI database lookup

Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21473

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I trial of micronized formulation carboxyamidotriazole in patients with refractory solid tumors: pharmacokinetics, clinical outcome, and comparison of formulations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21473

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I clinical and pharmacokinetic study of oral carboxyamidotriazole, a signal transduction inhibitor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21473

7 January 2021

based on heuristic

inferred from DOI database lookup

Angiogenesis: role of calcium-mediated signal transduction

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21473

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21473

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21473

7 January 2021

based on heuristic

inferred from DOI database lookup

The phase III candidate: can we improve the science of selection?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21473

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21473

7 January 2021

based on heuristic

inferred from DOI database lookup

A pilot study of antiangiogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21473

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21473

7 January 2021

based on heuristic

inferred from DOI database lookup

Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21473

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.21473

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/16222691

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/16222691

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46750687&oldid=2129819827"